Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat

Blood Purification

Volumn 25, Issue 5-6, 2008, Pages 466-472

  Van Westrhenen, Roos ^a   Aten, Jan ^a   Hajji, Najat ^a   De Boer, Onno J ^a   Kunne, Cindy ^a   De Waart, Dirk R ^a   Krediet, Raymond T ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Cyclosporin; Fibrosis; Peritoneal dialysis

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; GLUCOSE; LACTIC ACID; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LONG TERM CARE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; TISSUE SECTION;

ANIMALS; CYCLOSPORINE; FIBROSIS; GLUCOSE; HEMODIALYSIS SOLUTIONS; LACTIC ACID; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEAL DISEASES; RATS; RATS, WISTAR;

EID: 38849117240     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112475     Document Type: Article

References (30)

1. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG: Encapsulating peritoneal sclerosis: definition, etiology, diagnosis and treatment. Perit Dial Int 2000;20(suppl 4):S43-S55.
2. Rigby JR, Hawley CM: Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998;13:154-159.
3. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Beraud JJ: Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 1983;29:633-638.
4. Oules R, Challah S, Brunner FP: Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988;3:66-69.
5. Moriish M, Kawanisji H, Kawai T, Takahashi S, Hirai T: Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002;18:149-153.
6. Hendriks PMEM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SSKS, Sie L, Kox C, Krediet RT: Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 1997;17:136-143.
7. Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K: Effect of anti-transforming growth factor-beta antibodies in cyclosporin-induced renal dysfunction. Kidney Int 2001;59:498-506.
8. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
9. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853-861.
10. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, Krediet RT: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517-525.
11. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT: Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999;134:124-132.
12. Pannekeet MM, Imholz AL, Struijk DG, Koomen GCM, Langedijk MJ, Schouten N, de Waart DR, Hiralall JK, Krediet RT: The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995;48:866-875.
13. Smit W, van Dijk P, Schouten N, Langedijk M, van den Berg N, Struijk DG, Krediet RT: Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003;23:440-449.
14. Zweers MM, Splint LJ, Krediet RT, Struijk DG: Effect of fluid supplementation and modality on peritoneal permeability characteristics in a rat peritoneal dialysis model. Perit Dial Int 2001;21:58-64.
15. Koomen GCM, Krediet RT, Leegwater ACK, Struijk DG, Arisz L, Hoek FJ: A fast reliable method for the measurement of intra-peritoneal dextran 70 used to calculate lymphatic absorption. Adv Perit Dial 1991;7:10-14.
16. Krediet RT, Struijk DG, Koomen GM, Arisz L: Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991;37:662-667.
17. Waniewski J, Werynski A, Heimburger O, Lindholm B: Simple models for description of small-solute transport in peritoneal dialysis. Blood Purif 1991;9:129-141.
18. Zweers MM, Imholz AL, Struijk DG, Krediet RT: Correction of sodium sieving for diffusion from the circulation. Adv Perit Dial 1999;15:65-72.
19. van Westrhenen R, de Waart DR, Akman S, Krediet RT: Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurements. Perit Dial Int 2004;24:290-292.
20. Van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R: Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant 2005;20:6-10.
21. Myers BD, Ross JC, Newton LD, Luetscher JA, Perlroth MG: Cyclosporine-associated chronic nephropathy. N Engl J Med 1984;31:699-705.
22. 1 in experimental chronic cyclosporin nephropathy. Kidney Int 1996;49:1141-1151.
23. Shin GT, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Suthanthiran M: In vivo expression of transforming growth factor-β in humans. Transplantation 1998;65:3313-3318.
24. Shihab FS, Bennett WM, Yi H, Andoh TF: Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/FLK-1 in chronic cyclosporin nephrotoxicity. Transplantation 2001;72:164-168.
25. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT;Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
26. Di Paolo N, Sacchi G: Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989;9:41-45.
27. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, Yamamoto H, Yokoyama K, Kawaguchi Y, Matsushima M: Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005;9:148-152.
28. Io H, Hamada C, Ro Y, Ito Y, Hirahara J, Tomino Y: Morphologic changes of the peritoneum and expression of VEGF in encapsulating peritoneal sclerosis rat models. Kidney Int 2004;65:1927-1936.
29. Zarrinkalam KH, Stanley JM, Graay J, Oliver N, Faull RJ: Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients. Kidney Int 2003;64:331-338.
30. Zweers MM, Splint LJ, Krediet RT, Struijk DG: Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001;16:651-654.